Compile Data Set for Download or QSAR
maximum 50k data
Found 28 Enz. Inhib. hit(s) with all data for entry = 646
TargetPlasma kallikrein(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM285517(5-({2-[4-(5-Chloro-2-cyanophenyl)-5-methoxy-2-oxop...)
Affinity DataIC50:  0.800nMpH: 7.4 T: 2°CAssay Description:To determine the plasma kallikrein inhibition of the substances according to the invention, a biochemical test system is used which utilizes the reac...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM285515(5-({2-[4-(5-Chloro-2-cyanophenyl)-5-methoxy-2-oxop...)
Affinity DataIC50:  2.5nMpH: 7.4 T: 2°CAssay Description:To determine the plasma kallikrein inhibition of the substances according to the invention, a biochemical test system is used which utilizes the reac...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM285515(5-({2-[4-(5-Chloro-2-cyanophenyl)-5-methoxy-2-oxop...)
Affinity DataIC50:  2.70nMpH: 7.4 T: 2°CAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM285517(5-({2-[4-(5-Chloro-2-cyanophenyl)-5-methoxy-2-oxop...)
Affinity DataIC50:  2.70nMpH: 7.4 T: 2°CAssay Description:To determine the plasma kallikrein inhibition of the substances according to the invention, a biochemical test system is used which utilizes the reac...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM285522(5-({2-[4-(5-Chloro-2-cyanophenyl)-5-methoxy-2-oxop...)
Affinity DataIC50:  3nMpH: 7.4 T: 2°CAssay Description:To determine the plasma kallikrein inhibition of the substances according to the invention, a biochemical test system is used which utilizes the reac...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM285527(5-({2-[4-(5-Chloro-2-cyanophenyl)-5-methoxy-2-oxop...)
Affinity DataIC50:  3.80nMpH: 7.4 T: 2°CAssay Description:To determine the plasma kallikrein inhibition of the substances according to the invention, a biochemical test system is used which utilizes the reac...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM285521(5-({2-[4-(5-Chloro-2-cyanophenyl)-5-methoxy-2-oxop...)
Affinity DataIC50:  3.80nMpH: 7.4 T: 2°CAssay Description:To determine the plasma kallikrein inhibition of the substances according to the invention, a biochemical test system is used which utilizes the reac...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM285525(5-({2-[4-(5-Chloro-2-cyanophenyl)-5-methoxy-2-oxop...)
Affinity DataIC50:  5nMpH: 7.4 T: 2°CAssay Description:To determine the plasma kallikrein inhibition of the substances according to the invention, a biochemical test system is used which utilizes the reac...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM285514(5-({2-[4-(5-Chloro-2-cyanophenyl)-5-methoxy-2-oxop...)
Affinity DataIC50:  5nMpH: 7.4 T: 2°CAssay Description:To determine the plasma kallikrein inhibition of the substances according to the invention, a biochemical test system is used which utilizes the reac...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM285526(5-({2-[4-(5-Chloro-2-cyanophenyl)-5-methoxy-2-oxop...)
Affinity DataIC50:  5.20nMpH: 7.4 T: 2°CAssay Description:To determine the plasma kallikrein inhibition of the substances according to the invention, a biochemical test system is used which utilizes the reac...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM285517(5-({2-[4-(5-Chloro-2-cyanophenyl)-5-methoxy-2-oxop...)
Affinity DataIC50:  5.40nMpH: 7.4 T: 2°CAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM285520(5-({2-[4-(5-Chloro-2-cyanophenyl)-5-methoxy-2-oxop...)
Affinity DataIC50:  6.40nMpH: 7.4 T: 2°CAssay Description:To determine the plasma kallikrein inhibition of the substances according to the invention, a biochemical test system is used which utilizes the reac...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM285524(5-({2-[4-(5-Chloro-2-cyanophenyl)-5-methoxy-2-oxop...)
Affinity DataIC50:  6.60nMpH: 7.4 T: 2°CAssay Description:To determine the plasma kallikrein inhibition of the substances according to the invention, a biochemical test system is used which utilizes the reac...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM285523(5-({2-[4-(5-Chloro-2-cyanophenyl)-5-methoxy-2-oxop...)
Affinity DataIC50:  9.5nMpH: 7.4 T: 2°CAssay Description:To determine the plasma kallikrein inhibition of the substances according to the invention, a biochemical test system is used which utilizes the reac...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM285516(5-({2-[4-(5-Chloro-2-cyanophenyl)-5-methoxy-2-oxop...)
Affinity DataIC50:  11nMpH: 7.4 T: 2°CAssay Description:To determine the plasma kallikrein inhibition of the substances according to the invention, a biochemical test system is used which utilizes the reac...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM285517(5-({2-[4-(5-Chloro-2-cyanophenyl)-5-methoxy-2-oxop...)
Affinity DataIC50:  13nMpH: 7.4 T: 2°CAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM285514(5-({2-[4-(5-Chloro-2-cyanophenyl)-5-methoxy-2-oxop...)
Affinity DataIC50:  17nMpH: 7.4 T: 2°CAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM285527(5-({2-[4-(5-Chloro-2-cyanophenyl)-5-methoxy-2-oxop...)
Affinity DataIC50:  18nMpH: 7.4 T: 2°CAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
TargetPlasma kallikrein(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM285519(5-({2-[4-(5-Chloro-2-cyanophenyl)-5-methoxy-2-oxop...)
Affinity DataIC50:  18nMpH: 7.4 T: 2°CAssay Description:To determine the plasma kallikrein inhibition of the substances according to the invention, a biochemical test system is used which utilizes the reac...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM285522(5-({2-[4-(5-Chloro-2-cyanophenyl)-5-methoxy-2-oxop...)
Affinity DataIC50:  28nMpH: 7.4 T: 2°CAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM285521(5-({2-[4-(5-Chloro-2-cyanophenyl)-5-methoxy-2-oxop...)
Affinity DataIC50:  29nMpH: 7.4 T: 2°CAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM285525(5-({2-[4-(5-Chloro-2-cyanophenyl)-5-methoxy-2-oxop...)
Affinity DataIC50:  33nMpH: 7.4 T: 2°CAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM285526(5-({2-[4-(5-Chloro-2-cyanophenyl)-5-methoxy-2-oxop...)
Affinity DataIC50:  38nMpH: 7.4 T: 2°CAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM285524(5-({2-[4-(5-Chloro-2-cyanophenyl)-5-methoxy-2-oxop...)
Affinity DataIC50:  44nMpH: 7.4 T: 2°CAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM285523(5-({2-[4-(5-Chloro-2-cyanophenyl)-5-methoxy-2-oxop...)
Affinity DataIC50:  47nMpH: 7.4 T: 2°CAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM285520(5-({2-[4-(5-Chloro-2-cyanophenyl)-5-methoxy-2-oxop...)
Affinity DataIC50:  51nMpH: 7.4 T: 2°CAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM285519(5-({2-[4-(5-Chloro-2-cyanophenyl)-5-methoxy-2-oxop...)
Affinity DataIC50:  93nMpH: 7.4 T: 2°CAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCoagulation factor XI(Homo sapiens (Human))
Bayer Pharma Aktiengesellschaft

US Patent
LigandPNGBDBM285516(5-({2-[4-(5-Chloro-2-cyanophenyl)-5-methoxy-2-oxop...)
Affinity DataIC50:  120nMpH: 7.4 T: 2°CAssay Description:The factor XIa inhibition of the substances according to the invention is determined using a biochemical test system which utilizes the reaction of a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent